gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Kallikrein-related peptidase 13

KLK13, kallikrein 13, KLK-L4
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer. An additional transcript variant has been identified, but its full length sequence has not been determined. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Kallikrein, KLK6, KLK5, KLK14, HNP
Papers on KLK13
Expression and bioregulation of the kallikrein-related peptidases family in the human neutrophil.
Figueroa et al., Valdivia, Chile. In Innate Immun, Aug 2015
RT-PCR showed that blood neutrophils expressed only KLK1, KLK4, KLK10, KLK13, KLK14 and KLK15 mRNAs, whereas the non-differentiated HL-60 cells expressed most of them, with exception of KLK3 and KLK7.
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
Courty et al., Tours, France. In Tumour Biol, Jul 2015
The KLK13 gene is dysregulated in several carcinomas, and its expression levels seem to be associated with disease prognosis.
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery.
Harbeck et al., München, Germany. In Oncol Lett, 2015
In a previous study, we established the OVSCORE, an algorithm to predict surgical outcome, based on the clinical factors of nuclear grading and ascitic fluid volume, plus the cancer biomarkers, kallikrein-related peptidases (KLKs), KLK6 and KLK13.
Decreased expression of kallikrein-related peptidase 13: possible contribution to metastasis of human oral cancer.
Uzawa et al., Chiba, Japan. In Mol Carcinog, 2014
Our previous microarray analyses showed that the gene kallikrein-related peptidase 13 (KLK13) was down-regulated in oral squamous cell carcinoma (OSCC) cell lines.
Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Meyer-Hoffert et al., Kiel, Germany. In J Invest Dermatol, 2014
Recombinant Spink6 efficiently inhibited mouse Klk5 and human KLK2, KLK4, KLK5, KLK6, KLK7, KLK12, KLK13, and KLK14, whereas human KLK1 and KLK8 were not inhibited.
Alteration of gene expression and DNA methylation in drug-resistant gastric cancer.
Goto et al., Nagoya, Japan. In Oncol Rep, 2014
Expression of 15 genes including KLK13 increased and 12 genes including ETV7 decreased, in both drug-resistant cells and biopsy specimens of two patients after chemotherapy.
The structural network of Interleukin-10 and its implications in inflammation and cancer.
Nussinov et al., In Bmc Genomics, 2013
Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing β-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Australian Prostate Cancer BioResource et al., Brisbane, Australia. In Urol Oncol, 2013
We sought to elucidate the role of common genetic variation in four of the Kallikrein genes, KLK5, KLK6, KLK12, and KLK13, in prostate cancer risk and tumor aggressiveness.
Elevated immunoglobulin to tissue KLK11 in patients with Sjögren syndrome.
Shao et al., Louisville, United States. In Cornea, 2013
METHODS: Sera from 11 patients diagnosed with SS, 8 patients with dry eye disease (DED), and 8 normal age/sex-matched controls (NL) were collected for detecting antibodies against tissue KLK1, KLK11, KLK12, and KLK13 by capture enzyme-linked immunosorbent assay.
The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.
Scorilas et al., Athens, Greece. In Tumour Biol, 2012
We have recently reported KLK13 clinical importance as a favorable prognostic biomarker for gastric cancer patients' survival.
Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease.
Pflugfelder et al., Irvine, United States. In Invest Ophthalmol Vis Sci, 2012
RESULTS: Autoantibodies against kallikrein 13 were identified in serum from dry-eye mice, but were undetectable in untreated controls.
Substrate specificity of kallikrein-related peptidase 13 activated by salts or glycosaminoglycans and a search for natural substrate candidates.
Juliano et al., São Paulo, Brazil. In Biochimie, 2011
Results indicate that KLK13 may play a role in the defense of the upper digestive apparatus and in male reproductive organs.
Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation.
Chang et al., Taiwan. In Biochem Biophys Res Commun, 2011
these results reveal the enhancing effects of KLK13 on tumor cell invasion and migration, and that it may serve as a diagnostic/prognostic marker and a potential therapeutic target for lung cancer.
Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Meyer-Hoffert et al., Kiel, Germany. In Peptides, 2011
Serine protease of Kazal-type (SPINK6) expressed in normal human skin is a potent natural inhibitor of Kallikrein-related peptidases, KLK12 and KLK13.
Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas.
Scorilas et al., Athens, Greece. In Clin Biochem, 2010
This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Doré et al., St. John's, Canada. In Br J Cancer, 2009
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Diamandis et al., Athens, Greece. In J Clin Oncol, 2004
PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary.
Human tissue kallikreins and testicular cancer.
Diamandis et al., Toronto, Canada. In Apmis, 2003
In testicular germ cell tumors, some tissue kallikrein genes, including KLK5, KLK10, KLK13 and KLK14, were found to be significantly down-regulated.
The new human kallikrein gene family: implications in carcinogenesis.
Obiezu et al., Toronto, Canada. In Trends Endocrinol Metab, 2000
Another five putative kallikrein genes, provisionally named KLK-L2, KLK-L3, KLK-L4, KLK-L5 and KLK-L6, have also been identified.
share on facebooktweetadd +1mail to friends